Comparative Pharmacology
Head-to-head clinical analysis: CEREBYX versus TOPAMAX SPRINKLE.
Head-to-head clinical analysis: CEREBYX versus TOPAMAX SPRINKLE.
CEREBYX vs TOPAMAX SPRINKLE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fosphenytoin is a prodrug of phenytoin, which stabilizes neuronal membranes by blocking voltage-gated sodium channels, thereby inhibiting repetitive firing of action potentials.
Topiramate is a sulfamate-substituted monosaccharide that blocks voltage-gated sodium channels, enhances GABA-A receptor activity, antagonizes AMPA/kainate glutamate receptors, and inhibits carbonic anhydrase (isoenzymes II and IV).
Loading dose: 15-20 mg PE/kg IV/IM (max 1500 mg PE); maintenance: 4-6 mg PE/kg/day IV/IM divided q12h or q8h. Switch to oral phenytoin at equivalent dose.
Initial dose: 25-50 mg orally once daily at bedtime for 1 week; then increase by 25-50 mg/day at weekly intervals to recommended maintenance dose of 200-400 mg/day in 2 divided doses.
None Documented
None Documented
The terminal elimination half-life of fosphenytoin (converted to phenytoin) is approximately 15 hours (range 10-20 hours) in adults with normal hepatic function; after conversion, phenytoin half-life is dose-dependent and averages 22 hours (range 7-42 hours) at therapeutic concentrations.
Terminal elimination half-life is approximately 21 hours in adults with normal renal function. This allows for twice-daily dosing. Half-life increases significantly in renal impairment (e.g., 36-46 hours in moderate to severe impairment).
Renal excretion of unchanged drug and metabolites accounts for approximately 80% of the dose; about 20% is eliminated in feces via biliary excretion.
Approximately 70% of a dose is excreted unchanged in the urine; the remainder is metabolized and eliminated via renal and biliary routes. Renal elimination of both parent drug and metabolites accounts for ~80%, with minimal fecal excretion.
Category C
Category C
Anticonvulsant
Anticonvulsant